Altimmune (ALT) Enterprise Value (2010 - 2026)
Altimmune (ALT) posted quarterly Enterprise Value of -$331.6 million for Q1 2026, down 574.11% year-over-year from $69.9 million in Q1 2025, and down 656.28% quarter-over-quarter from -$43.8 million in Q4 2025.
Altimmune (ALT) Enterprise Value (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Enterprise Value for 17 consecutive years, with -$331.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 574.11% year-over-year to -$331.6 million; the TTM figure through Mar 2026 stood at -$331.6 million (down 574.11% YoY), while the FY2025 annual figure was -$43.8 million, down 18.47% from the prior year.
- Enterprise Value declined to -$331.6 million in Q1 2026 per ALT's latest filing, from -$43.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$37.0 million in Q4 2024 and bottomed at -$331.6 million in Q1 2026.
- Historically, Enterprise Value has averaged -$128.9 million across 5 years, with a median of -$111.2 million in 2022.
- Annual changes were most pronounced in 2025 — Enterprise Value jumped 72.98% — and 2026, when it plunged 574.11%.
- Altimmune's Enterprise Value stood at -$111.2 million in 2022, then dropped by 21.62% to -$135.2 million in 2023, then soared by 72.63% to -$37.0 million in 2024, then fell by 18.47% to -$43.8 million in 2025, then plunged by 656.28% to -$331.6 million in 2026.
- Business Quant data shows ALT's Enterprise Value at -$331.6 million in Q1 2026, -$43.8 million in Q4 2025, and -$61.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -326.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -326.32 Mn |
| Mar 31, 2026 | -331.58 Mn |
| Dec 31, 2025 | -43.84 Mn |
| Sep 30, 2025 | -61.28 Mn |
| Jun 30, 2025 | -183.19 Mn |
| Mar 31, 2025 | -49.19 Mn |
| Dec 31, 2024 | -37.01 Mn |
| Sep 30, 2024 | -139.42 Mn |
| Jun 30, 2024 | -57.21 Mn |
| Mar 31, 2024 | -182.07 Mn |
| Dec 31, 2023 | -135.20 Mn |
| Sep 30, 2023 | -86.94 Mn |
| Jun 30, 2023 | -102.43 Mn |
| Mar 31, 2023 | -104.76 Mn |
| Dec 31, 2022 | -111.17 Mn |
| Sep 30, 2022 | -201.86 Mn |
| Jun 30, 2022 | -184.79 Mn |
| Mar 31, 2022 | -180.02 Mn |
| Dec 31, 2021 | -190.37 Mn |
| Sep 30, 2021 | -199.92 Mn |